胰高血糖素样肽1受体激动剂对肥胖或超重患者体重、BMI和腰围的疗效:47项随机对照试验的系统评价、Meta分析和Meta回归
该系统评价与Meta分析纳入47项随机对照试验共23244例肥胖或超重成人,评估胰高血糖素样肽1受体激动剂(GLP-1 RAs)对体重、BMI和腰围的影响。与安慰剂相比,GLP-1 RAs平均降低体重-4.57 kg、BMI -2.07 kg/m2、腰围-4.55 cm,效应在糖尿病状态、药物种类和给药途径间一致。
要点
- GLP-1 RAs较安慰剂平均降低体重4.57 kg、BMI 2.07 kg/m2、腰围4.55 cm。
- 减重效应在有无糖尿病、不同GLP-1 RA及给药途径间保持一致。
- 年轻、女性、无糖尿病、基线体重和BMI较高而HbA1c较低及疗程较长者获益可能更大。
核心结论
- GLP-1 RAs在肥胖或超重成人中显示出显著的体重、BMI和腰围降低获益。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane CENTRAL从建库至2024年10月4日发表的随机对照试验,限成人肥胖或超重伴或不伴糖尿病。
- 共纳入47项随机对照试验,合计23244例患者。
- 由两名独立评价者进行文献检索和数据提取,分歧通过共识或第三评价者咨询解决。
主要发现
- 与安慰剂相比,GLP-1 RAs平均降低体重-4.57 kg(95%CI -5.35至-3.78)。
- 与安慰剂相比,GLP-1 RAs平均降低BMI -2.07 kg/m2(95%CI -2.53至-1.62)。
- 与安慰剂相比,GLP-1 RAs平均降低腰围-4.55 cm(95%CI -5.72至-3.38)。
- 该效应在糖尿病状态、所用GLP-1 RA和给药途径间保持一致。
- 最大治疗获益似乎倾向于较年轻、女性、无糖尿病、基线体重和BMI较高但基线HbA1c较低及治疗时间较长的患者。
关键数值与推荐
- 纳入标准为评估GLP-1 RAs对成人肥胖或超重(伴或不伴糖尿病)体重、BMI和腰围较基线平均差值的随机对照试验。
临床怎么用
- 原文未据此给出推荐。
局限性
- 存在显著的统计学异质性,部分源于宽泛的纳入标准。
- 这种异质性可能通过反映广泛的研究设计和患者人群而提高普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity. RESEARCH DESIGN AND METHODS: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes. Two independent reviewers performed the literature search and data extraction, resolving disagreements via consensus or third-reviewer consultation. RESULTS: Forty-seven RCTs were included, with a combined cohort of 23,244 patients. GLP-1 RAs demonstrated a mean weight reduction of -4.57 kg (95% CI -5.35 to -3.78), mean BMI reduction of -2.07 kg/m2 (95% CI -2.53 to -1.62), and mean waist circumference reduction of -4.55 cm (95% CI -5.72 to -3.38) compared with placebo. This effect was consistent across diabetes status, GLP-1 RA used, and route of administration. The greatest treatment benefit appeared to favor patients who were younger, female, without diabetes, with higher baseline weight and BMI but lower baseline HbA1c, and treated over a longer duration. Limitations include substantial statistical heterogeneity, in part due to broad inclusion criteria. However, this heterogeneity may improve generalizability by reflecting a wide range of study designs and patient populations. CONCLUSIONS: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
引用
- Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials. Diabetes Care. 2025. PMID: 39841962. doi:10.2337/dc24-1678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。